The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | CRCI and compromised adjuvant chemotherapy delivery in cancer
Filippos Koinis, MD, PhD, University of Thessaly, Larissa, Greece, explores the association between early cancer-related cognitive impairment (CRCI) and chemotherapy treatment delivery outcomes in patients with early-stage breast cancer or colorectal cancer receiving adjuvant chemotherapy. Results demonstrated that early CRCI was significantly associated with reduced relative dose intensity, higher rates of treatment discontinuation, and increased treatment delays, identifying early CRCI as a clinically actionable target for risk-adapted supportive strategies to preserve curative-intent treatment delivery. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
